ARWR
Arrowhead PharmaceuticalsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ARWR Profile
Arrowhead Pharmaceuticals, Inc.
A developer of RNAi interference and peptide drug conjugates for a wide range of diseases
177 E. Colorado Blvd, Suite 700, Pasadena, California 91105
--
Arrowhead Pharmaceuticals, Inc., originally incorporated in South Dakota in 1989, was re-incorporated in Delaware. The company develops drugs to treat intractable diseases by silencing the genes of diseases. Using a wide range of RNA chemical combinations and highly efficient delivery modes, the company's therapies trigger RNA interference mechanisms to induce rapid, deep and persistent knockdown of target genes. There are currently 18 Arrowhead drug candidates in early (Phase 1) to late (Phase 3) clinical trials.
